← boardnext 2026-09-01
ARDX
Ardelyxdistress 4/10 · elevated risk$4.99-2%today-38% from 52w high
Gastroenterology 1
Lead: Irritable Bowel Syndrome With Constipation (IBS-C) · target NHE3
Revenue
$94M
Liquidity
$31M
Runway
0.9 yrs
Shares 1y
+3%
Price & events
-37.1% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.9%
1D
-2.7%
1W
-19.3%
1M
-16.4%
3M
-35.8%
6M
+13.6%
1Y
-12.4%
2Y
+196.7%
5Y
-23.0%
All
Overview
- Market Cap
- $1.23B
- Enterprise Value
- $1.40B
- Volume
- 432.62K
- 52 Week Range
- $4.22 – $7.99
- Total Shares
- 247.03M
- Float Shares
- 219.80M
- Short %
- 10.50%
- % Held by Insiders
- 3.28%
- % Held by Institutions
- 70.76%
- RVOL
- 0.11x
- Beta
- 0.60
Pipeline stages · 1 programs
Tenapanor
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 4 trials · 3 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-09-01 Estimated 50% readout ~2026-11-15 | Phase 3 | Tenapanor 50 MG, Tenapanor 25 mg bid | Irritable Bowel Syndrome With Constipation (IBS-C) | — | active not recruiting |
| 2027-02-26 Estimated 50% readout ~2027-05-12 | Phase 3 | Tenapanor 5 mg BID, Tenapanor 25 mg BID, Tenapanor 50 mg BID | Chronic Idiopathic Constipation (CIC) | — | recruiting |
| 2031-07 Estimated 50% readout ~2031-09-14 | Phase 3 | Tenapanor | Irritable Bowel Syndrome With Constipation (IBS-C) | — | enrolling by invitation |
| 2026-07 | Phase 2 | Tenapanor | Irritable Bowel Syndrome With Constipation (IBS-C) | 72 | active not recruiting |
Catalyst news & presentations · 1
- 2026-08-06earningsEarningsEarnings releaseyahoo
Approved drugs (2)
- XPHOZAHTENAPANOR HYDROCHLORIDE2023 · Prescription
- IBSRELATENAPANOR HYDROCHLORIDE2019 · Prescription
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $16 (+227% upside) · 10 analysts
- 2026-02-23WedbushOutperform
- 2026-02-20BTIGBuy
- 2026-02-20HC Wainwright & Co.Buy
- 2026-01-29BTIGBuy
- 2026-01-21WedbushOutperform
- 2026-01-09CitigroupBuy
Competitors — NHE3
- none identified
Recent news
- 2026-07-23Ardelyx to Report Second Quarter 2026 Financial Results on August 6, 2026 - The Manila Times
- 2026-07-23Ardelyx to Report Second Quarter 2026 Financial Results on August 6, 2026 - GlobeNewswire
- 2026-07-22ETFs Investing in Ardelyx, Inc. Stocks - TradingView
- 2026-07-22How Investors Are Reacting To Ardelyx (ARDX) Hedge Fund Buying Despite Medicare Setback - simplywall.st
- 2026-07-20Claude AI Says Market is Ignoring Ardelyx (ARDX) Growth Catalysts - Yahoo Finance
- 2026-07-20ARDX Stock Is Down Pre-Market After Q4 Earnings Miss, So Why Did This Firm Just Hike Price Target By 80%? - Stocktwits
- 2026-07-18ARDX Edges Up After Hours On IBSRELA Momentum And Profitability ‘Right Around The Corner’ - Stocktwits
- 2026-07-18Ardelyx (ARDX) Pulls Back As Growth Narrative Raises The Question Of Value - simplywall.st
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.